Aerobic exercise to reduce heart risk in people with rheumatoid arthritis or chronic kidney disease
Official title: Effects of an Aerobic Exercise Program on Cardiovascular Risk in Patients With Chronic Kidney Disease or Rheumatoid Arthritis
Run by University of Franche-Comté · NCT07469540 · Data updated 2026-11-12
This program will test whether a six-week individualized aerobic exercise plan can lower heart-related risk in people with rheumatoid arthritis or stage III–IV chronic kidney disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | All |
| Enrollment | 90 (estimated) |
| Sponsor | University of Franche-Comté Academic / other |
| Drugs / interventions | prednisone |
| Locations | 1 site (Besançon) |
| Status | Recruiting |
| Started | March 16, 2026 |
| Main results expected | December 31, 2026 |
| Study ends | December 31, 2026 |
| Registry record updated | March 13, 2026 |
| Trial ID | NCT07469540 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are adults with rheumatoid arthritis (DAS28 ≥ 2.6) or chronic kidney disease stage III–IV (eGFR 20–45 ml/min/1.73 m²) who are medically cleared to exercise and covered by the French social security system.
✕Probably not a fit
Patients who cannot safely perform exercise (due to uncontrolled blood pressure, active high-dose corticosteroid use, pregnancy, major cognitive impairment, severe comorbidities preventing exercise, or legal incapacity) are unlikely to benefit from the program.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Researchers will randomize participants with rheumatoid arthritis or stage III–IV chronic kidney disease to an individualized aerobic exercise program, a therapeutic education program delivered by phone, or no intervention. The exercise group will perform three 45-minute sessions per week for six weeks at 60–80% of heart rate reserve, with clinic visits at baseline, after the 6-week intervention, and at a 6-week follow-up. Outcomes include measures of arterial stiffness and endothelial function (for example pulse wave velocity), plus blood analyses of inflammation and markers of immunosenescence. The trial compares physiological and blood-biomarker changes between groups to see if the exercise program produces clinically meaningful cardiovascular benefits.
Why it matters
Potential benefit: If successful, the program could improve arterial stiffness and reduce systemic inflammation, lowering cardiovascular risk and potentially improving long-term outcomes for these patients.
How similar studies have gone: Prior studies show aerobic exercise can improve vascular function and reduce inflammation in people with chronic inflammatory conditions, but applying a short individualized 6-week program specifically to CKD or RA patients with evaluation of immunosenescence is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosis of Chronic Kidney Disease (CKD) or Rheumatoid Arthritis (RA), with no other risk factors related to the disease. * Having a glomerular filtration rate between 45 and 20 ml/min/1.73 m², corresponding to stages III and IV not on dialysis for patients with CKD ; or have a DAS 28 score ≥ 2.6 points for patients with RA. * Have a medical certificate stating that there are no adverse reactions to physical activity. * Affiliation with a French social security scheme or beneficiary of such a scheme. Exclusion Criteria: * Unstabilised corticosteroid therapy and/or \>10mg prednisone/day * Uncontrolled high blood pressure * Pregnant women * Impaired higher functions making it impossible to understand and adhere to an aerobic exercise program * Inability to perform physical exercise, regardless of the cause (neurological, central or peripheral, cardiovascular or respiratory, or musculoskeletal) * Legal incapacity or limited legal capacity * Subject unlikely to cooperate with the study and/or low cooperation anticipated by the investigator * Subject without health insurance * Subject is in the exclusion period of another study involving human subjects that may interfere with the results of this study, particularly by affecting inflammatory status and the cardiovascular system.
Where it's running
-
EPHI Platform
Besançon, France Recruiting
Study contacts
- Study coordinator: Jérôme Bouchan, PhD
- Email: jerome.bouchan@umlp.fr
- Phone: +33363082323
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Observational look at how Kremezin works in adults with advanced chronic kidney disease
This study tests whether Kremezin helps adults with advanced kidney disease when used as part of routine care, by tracking safety and kidney function over up to 48 weeks.
-
Air filters at home to see if breathing cleaner air helps heart health in obesity
This study tests whether portable air filtration systems can improve cardiovascular risk factors in adults with obesity and high blood pressure.
-
Kidney and Heart Health in Adults with Type 2 Diabetes and CKD Treated with Semaglutide in China
This study tests whether semaglutide injections help kidney and heart health in adults with type 2 diabetes and chronic kidney disease.
-
High BMI and periodontitis in Thai adults under 60
This study tests how common high BMI and periodontitis are among Thai adults aged 18–59 and what factors are linked to them.
-
Comparison of Different Exercise Protocols for Lipedema
This study tests whether high‑intensity interval training or moderate‑intensity continuous training improves function, strength, and quality of life in adults with lipedema.
-
Bringing preventive cardiovascular care to Indigenous and remote communities
This project tests a mobile health unit to screen and provide culturally safe cardiovascular and metabolic care for Indigenous and remote communities in Canada.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.